CRISIL believes the Indian pharmaceutical industry will weather the current headwinds of slowdown in exports caused by regulatory scrutiny and intensifying competition, by monetising opportunities in complex products in the regulated markets, and because of resilient domestic demand. The sector's ...
Read more: Complex generics to help pharma weather regulated market de-growth: Crisil